Indeed, the possibility of finding a co-expression of BMI1 and CD26 in CML-LSC could have as clinical consequence the possibility of using the BMI1 inhibitors (today available for the clinical use) for attempting to eliminate LSCs and eventually overcome the resistance to TKIs. Here, DPP4 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.